The Global Geographic Atrophy (GA) Market is driven by the increasing prevalence of age-related macular degeneration (AMD), of which GA is an advanced form. According to the BrightFocus Foundation, approximately 196 million people worldwide are affected by AMD, with an estimated 10-15% progressing to GA. The prevalence of GA significantly increases with age, impacting nearly 5% of individuals over 75 years old in developed regions like the U.S. and Europe. Advances in diagnostic imaging, such as Optical Coherence Tomography (OCT), have improved early detection rates, allowing for timely intervention. Additionally, the market is bolstered by rising awareness of GA among aging populations and ongoing research into innovative therapies targeting the complement pathway and neuroprotection. However, the lack of curative treatments remains a critical challenge, underscoring the urgent need for novel therapeutic developments.
